Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | CASP6 | P55212 | 1/20 | 0.44 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | HCAR3 | P49019 | 6/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27313061 | 0.84 | TSHR (0.58) | TSHRCASP6MRGPRX4ALDH1A1HCAR3 | |
| SCHEMBL27637429 | 0.83 | MRGPRX4 (0.51) | TSHRMRGPRX4ALDH1A1CYP1A2POLB | |
| SCHEMBL27754168 | 0.83 | POLB (0.47) | TSHRCASP6ALDH1A1HCAR3LMNA | |
| SCHEMBL27905721 | 0.82 | ALDH1A1 (0.42) | TSHRALDH1A1LMNACYP1A2CYP3A4 | |
| SCHEMBL27826347 | 0.81 | MRGPRX4 (0.44) | TSHRCASP6MRGPRX4ALDH1A1HCAR3 | |
| SCHEMBL27634015 | 0.81 | TSHR (0.49) | TSHRCASP6ALDH1A1LMNACYP1A2 | |
| SCHEMBL2001751 | 0.81 | LMNA (0.55) | TSHRCASP6ALDH1A1HCAR3LMNA | |
| SCHEMBL27845365 | 0.81 | HCAR3 (0.58) | ALDH1A1HCAR3MEN1KMT2A | |
| SCHEMBL27664713 | 0.80 | CASP6 (0.42) | TSHRCASP6ALDH1A1HCAR3LMNA | |
| SCHEMBL27630869 | 0.79 | HTR7 (0.46) | TSHRCASP6ALDH1A1HCAR3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080125358-A1 | Methods for Chk2 inhibitor patient selection | UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL | 2008-05-29 | — | — | US | disclosed |
| CN-1088702-C | Disubstituted bicyclic heterocycles, their production and use as medicaments | BOEHRINGER INGELHEIM PHARMA (DE) | 2002-08-07 | — | — | CN | disclosed |
| CN-1248251-A | Disubstituted bicyclic heterocycles, their production and use as medicaments | BOEHRINGER INGELHEIM PHARMA (DE) | 2000-03-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125358-A1 | Methods for Chk2 inhibitor patient selection | CHEK2, CHEK1, TP53 | TSHR 1518/4885CASP6 724/4885MRGPRX4 4341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.